Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.

doi:10.1158/1078-0432.CCR-18-0981

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Feb 2019

de Bono Johann S, De Giorgi Ugo, Rodrigues Daniel Nava, Massard Christophe, Bracarda Sergio, Font Albert, Arranz Arija Jose Angel, Shih Kent C, Radavoi George Daniel, Xu Na, Chan Wai Y, Ma Han, Gendreau Steven, Riisnaes Ruth, Patel Premal H, Maslyar Daniel J, Jinga Viorel

Abstract excerpt

PURPOSE: PI3K-Akt-mTOR and androgen receptor (AR) signaling are commonly aberrantly activated in metastatic castration-resistant prostate cancer (mCRPC), with PTEN loss associating with poor prognosis. We therefore conducted a phase Ib/II study of the combination of ipatasertib, an Akt inhibitor, with the CYP17 inhibitor abiraterone in patients with mCRPC.Patients and Methods: Patients were randomized 1:1:1 to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androstenes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Kaplan-Meier Estimate

Share to Piperazines

Share to Prostatic Neoplasms, Castration-Resistant

Share to Proto-Oncogene Proteins c-akt

Share to PTEN Phosphohydrolase

Share to Pyrimidines

Source

Open in PubMed

Identifiers

PMID: 30037818
DOI: 10.1158/1078-0432.CCR-18-0981

Genes

PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.PMID 30037818Read ↗

PIK3/Akt/mTOR pathway alterations in metastatic castration-sensitive prostate cancer.Semantic proximity Read ↗

Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K.Semantic proximity Read ↗

Clinical implications of PTEN loss in prostate cancer.Semantic proximity Read ↗

The PTEN Conundrum: How to Target PTEN-Deficient Prostate CancerSemantic proximity Read ↗

A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumors.Semantic proximity Read ↗

PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.Semantic proximity Read ↗

Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.Semantic proximity Read ↗

The TGF-β, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancerSemantic proximity Read ↗

PTEN regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progressionSemantic proximity Read ↗

Complex Impacts of PI3K/AKT Inhibitors to Androgen Receptor Gene Expression in Prostate Cancer CellsSemantic proximity Read ↗

Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancersSemantic proximity Read ↗

rAAV-Delivered PTEN Therapeutics for Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.